Relmada Therapeutics (RLMD) Projected to Post Quarterly Earnings on Monday

Relmada Therapeutics (NASDAQ:RLMD) is projected to issue its Q1 2026 results after the market closes on Monday, May 11th. Analysts expect the company to announce earnings of ($0.18) per share for the quarter. Parties can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Monday, May 11, 2026 at 4:30 PM ET.

Relmada Therapeutics (NASDAQ:RLMD) last released its quarterly earnings results on Thursday, March 19th. The company reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.13). On average, analysts expect Relmada Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Relmada Therapeutics Price Performance

RLMD traded down $0.09 during midday trading on Monday, reaching $7.56. 252,367 shares of the company’s stock traded hands, compared to its average volume of 1,468,607. The firm has a fifty day moving average of $6.31 and a two-hundred day moving average of $4.65. The stock has a market capitalization of $792.44 million, a price-to-earnings ratio of -5.21 and a beta of 0.43. Relmada Therapeutics has a 52 week low of $0.32 and a 52 week high of $7.94.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Janus Henderson Group PLC bought a new position in shares of Relmada Therapeutics in the 4th quarter worth approximately $35,041,000. Squadron Capital Management LLC bought a new position in shares of Relmada Therapeutics in the 4th quarter worth approximately $32,361,000. Adage Capital Partners GP L.L.C. bought a new position in shares of Relmada Therapeutics in the 4th quarter worth approximately $20,624,000. Marshall Wace LLP raised its position in shares of Relmada Therapeutics by 1,072.4% in the 4th quarter. Marshall Wace LLP now owns 3,189,662 shares of the company’s stock worth $15,406,000 after acquiring an additional 2,917,609 shares in the last quarter. Finally, Ikarian Capital LLC raised its position in shares of Relmada Therapeutics by 66.5% in the 4th quarter. Ikarian Capital LLC now owns 3,068,359 shares of the company’s stock worth $14,820,000 after acquiring an additional 1,225,299 shares in the last quarter. Institutional investors own 45.24% of the company’s stock.

Analysts Set New Price Targets

RLMD has been the subject of a number of recent analyst reports. Zacks Research raised Relmada Therapeutics to a “hold” rating in a research report on Tuesday, January 27th. Mizuho upped their price target on Relmada Therapeutics from $10.00 to $19.00 and gave the company an “outperform” rating in a research report on Friday, March 20th. Leerink Partners raised Relmada Therapeutics from a “market perform” rating to an “outperform” rating and set a $8.00 price target for the company in a research report on Friday, January 23rd. Piper Sandler assumed coverage on Relmada Therapeutics in a research report on Tuesday, March 24th. They set an “overweight” rating and a $12.00 price target for the company. Finally, Lucid Cap Mkts raised Relmada Therapeutics to a “strong-buy” rating in a research report on Monday, March 2nd. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $12.00.

Relmada Therapeutics Company Profile

Relmada Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies for pain and other central nervous system (CNS) disorders. The company applies a proprietary stereochemical approach to optimized drug candidates, aiming to improve safety, tolerability and efficacy profiles compared with existing treatments. Relmada’s research efforts center on modulation of NMDA receptors to address unmet needs in depression, neuropathic pain and related indications.

Relmada’s lead product candidate, REL-1017 (d-methadone), is being evaluated as a potential rapid-acting and maintenance treatment for major depressive disorder, with clinical studies underway to assess its utility in both acute and long-term settings.